Neosine Forte (Inosine Pranobex)

Inosine Pranobex, the active ingredient in Neosine Forte, is an immunomodulator presented as an oral formulation for oral use. It is employed to support the immune response in viral infections such as herpes simplex, human papillomavirus, and influenza, and may be considered in certain chronic systemic immunodeficiency conditions.

GNH USA supplies Neosine Forte as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics across multiple regions.

Neosine Forte (Inosine Pranobex) is employed as an antiviral immunomodulator to enhance host defenses across several viral disease categories. - Herpes simplex infections: shortens lesion healing time and reduces viral shedding. - Human papillomavirus (HPV) infections: supports clearance of cutaneous and mucosal lesions. - Influenza: mitigates symptom severity and may shorten disease duration. - Immunodeficiency conditions: augments cellular immunity to help control opportunistic viral infections.

Inosine Pranobex is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate stomach upset that may resolve without treatment. - Headache: transient cranial discomfort, often relieved with simple analgesics. - Dizziness: occasional light‑headedness, especially when standing quickly. - Rash: mild skin erythema or pruritus that typically subsides after discontinuation.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction characterized by hives, swelling, respiratory distress and hypotension; requires immediate medical attention. - Hepatotoxicity: elevated liver enzymes or clinical hepatitis, potentially leading to jaundice; monitor liver function during therapy. - Hematologic abnormalities: neutropenia, thrombocytopenia, or anemia that may increase infection or bleeding risk; regular blood counts are advised. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis presenting with extensive skin detachment and mucosal involvement; discontinue drug promptly.

When prescribing Neosine Forte, clinicians should consider several precautionary measures to ensure patient safety. - Renal impairment: assess kidney function and monitor for accumulation. - Hepatic dysfunction: evaluate liver enzymes before initiation and during treatment. - Immunocompromised patients: weigh benefits against potential overstimulation of immune response. - Pregnancy: use only if clearly indicated after risk‑benefit assessment. - Concomitant immunosuppressants: monitor for reduced efficacy or enhanced toxicity. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Inosine Pranobex may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Immunosuppressive agents: concurrent use may diminish the drug’s immunostimulatory effect. - Live vaccines: co‑administration can reduce vaccine‑induced immunity. - Anticoagulants: potential for increased bleeding risk due to platelet function changes.

Moderate Interactions (Monitor Closely): - Corticosteroids: may enhance immunomodulatory activity, requiring clinical observation. - Antiretroviral therapy: possible pharmacodynamic interaction that could affect viral control.